Abstract: Modular shelving systems, magnetic electrical connectors, conductor assemblies, and mounting inserts are disclosed. A modular shelving system includes at least one shelving module, a power module coupled to the at least one shelving module, and a conductor assembly coupled to the at least one shelving module and electrically connected to the power module. The conductor assembly includes a board including a first column of apertures and a second column of apertures, a back plate formed from a ferromagnetic material or from a magnetic material, a first conductor electrically coupled to the power module and positioned between the back plate and the board, and a second conductor electrically coupled to the power module and positioned between the back plate and the board. The first conductor is aligned with the first column of apertures of the board. The second conductor is aligned with the second column of apertures of the board.

Abstract: Modular shelving systems, magnetic electrical connectors, conductor assemblies, and mounting inserts are disclosed. A modular shelving system includes at least one shelving module, a power module coupled to the at least one shelving module, and a conductor assembly coupled to the at least one shelving module and electrically connected to the power module. The conductor assembly includes a board including a first column of apertures and a second column of apertures, a back plate formed from a ferromagnetic material or from a magnetic material, a first conductor electrically coupled to the power module and positioned between the back plate and the board, and a second conductor electrically coupled to the power module and positioned between the back plate and the board. The first conductor is aligned with the first column of apertures of the board. The second conductor is aligned with the second column of apertures of the board.

Abstract: A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixture of enantiomers of milnacipran enriched in the (1S,2R) enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts.

Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.

Abstract: A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixture of enantiomers of milnacipran enriched in the (1S, 2R) enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts.

Abstract: A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixture of enantiomers of milnacipran enriched in the (1S,2R) enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts.

Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.

Abstract: The present invention relates to a method for creating a blood bank in which blood samples are preserved and the values determined from the blood samples can be linked via suitable algorithms to a data bank in which clinical data and specialized medical knowledge are stored.

Abstract: The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.